Drug intelligence / Profile preview

ruxolitinib + trastuzumab

Development stage: Discontinued
Lead developer: Incyte
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Ruxolitinib + trastuzumab is an investigational combination therapy that was studied for the treatment of metastatic HER2-positive breast cancer. This combination pairs ruxolitinib, a JAK1/JAK2 inhibitor FDA-approved for myelofibrosis, with trastuzumab, an established HER2-targeted monoclonal antibody. The rationale for this combination was based on preclinical evidence showing that the IL6/JAK2/STAT3 signaling pathway is a master regulator in HER2+ breast cancer, and disruption of this pathway reduces HER2+ cell viability. In mouse xenograft models, the combination demonstrated synergistic tumor growth inhibition.

Targets

JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on ruxolitinib + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ruxolitinib + trastuzumab.

Explore the full profile